Heritability of metoprolol and torsemide pharmacokinetics

Clinical Pharmacology and Therapeutics
J MatthaeiR Kerb

Abstract

Genetic variation in the pharmacokinetics of metoprolol and torsemide due to polymorphisms in CYP2D6, CYP2C9, and OATP1B1 has been extensively studied. However, it is still unknown how much of the variation in pharmacokinetics of these two clinically important drugs in total is due to genetic factors. Metoprolol and torsemide were intravenously administered to 44 monozygotic and 14 dizygotic twin pairs. Metoprolol area under the curve (AUC) varied 4.7-fold and torsemide AUC 3.5-fold. A very high fraction of AUC variations, 91% of metoprolol and 86% of torsemide, were found to be due to additive genetic effects. However, known genetic variants of CYP2D6, -2C9, and OATP1B1 explained only 39%, 2%, and 39% of that variation, respectively. Comparable results for genetically explained variation in pharmacokinetics and pharmacodynamics have been found for other substrates of these enzymes earlier. These findings indicate that a substantial fraction of the heritable variability in the pharmacokinetics of metoprolol and torsemide remains to be elucidated.

References

Sep 17, 1977·Lancet·A MahgoubR L Smith
Feb 1, 1978·Heredity·N G MartinP Davies
Jan 1, 1979·Diabetes·J Scott, P L Poffenbarger
Jan 1, 1990·European Journal of Clinical Pharmacology·H SpahnE Mutschler
Jan 1, 1989·Pharmacology & Therapeutics·E S Vesell
Dec 1, 1968·The Journal of Clinical Investigation·E S Vesell, J G Page
Mar 29, 1968·Science·E S Vesell, J G Page
Jan 1, 1983·European Journal of Clinical Pharmacology·C G RegårdhP O Lagerström
Sep 1, 1981·Clinical Pharmacokinetics·C G RegårdhO Rönn
May 1, 1994·Behavior Genetics·M C NealeK S Kendler
Jul 1, 1993·Clinical Pharmacology and Therapeutics·S SchwartzD Rudy
Dec 17, 1997·Nature Genetics·N MartinG Machin
Apr 28, 2001·Trends in Molecular Medicine·B B SpearJ Huff
Oct 27, 2001·British Journal of Clinical Pharmacology·J A Goldstein
Jul 26, 2002·Briefings in Bioinformatics·Frühling V Rijsdijk, Pak C Sham
Nov 5, 2002·Nature Reviews. Genetics·Dorret BoomsmaLeena Peltonen
Feb 7, 2003·The New England Journal of Medicine·William E Evans, Howard L McLeod
Nov 18, 2003·Naunyn-Schmiedeberg's Archives of Pharmacology·Ulrich M ZangerMichel Eichelbaum
Oct 8, 2004·Clinical Pharmacology and Therapeutics·Julia KirchheinerJürgen Brockmöller
Dec 14, 2004·Clinical Pharmacology and Therapeutics·Stefan Viktor VormfeldeJürgen Brockmöller
Jul 3, 2008·The Annals of Pharmacotherapy·Chuenjid KongkaewDarren M Ashcroft
Jan 1, 2008·Statistics Surveys·Mingyan Huang, Daowen Zhang
May 24, 2011·Pharmacogenomics·Daniel SehrtJürgen Brockmöller
Nov 17, 2012·Expert Opinion on Drug Metabolism & Toxicology·Andreas HolsteinPeter Kovacs
May 15, 2013·Clinical Pharmacology and Therapeutics·C M BlakeP Nagele
Aug 8, 2013·British Journal of Clinical Pharmacology·Talitha I VerhoefAnke-Hilse Maitland-van der Zee
Mar 5, 2015·Pharmacogenetics and Genomics·Tore B StageKim Brosen

❮ Previous
Next ❯

Citations

Apr 12, 2016·Clinical Pharmacology and Therapeutics·I Cascorbi, M Schwab
Oct 19, 2016·International Journal of Molecular Sciences·Volker M Lauschke, Magnus Ingelman-Sundberg
Aug 11, 2016·Clinical Pharmacology and Therapeutics·J MatthaeiJ Brockmöller
Nov 29, 2017·The AAPS Journal·Volker M LauschkeMagnus Ingelman-Sundberg
Jan 10, 2018·Clinical Pharmacology and Therapeutics·Volker M Lauschke, Magnus Ingelman-Sundberg
Mar 1, 2018·Frontiers in Genetics·Jeremy T HowardChristian Maltecca
May 26, 2018·Human Genomics·Magnus Ingelman-SundbergVolker M Lauschke
Sep 26, 2020·Frontiers in Genetics·Johannes MatthaeiJürgen Brockmöller
Nov 13, 2019·Clinical Pharmacology and Therapeutics·Rawan ShekhaniMagnus Ingelman-Sundberg
Sep 28, 2017·Experimental Biology and Medicine·Daniel F Carr, Munir Pirmohamed
Nov 21, 2020·Omics : a Journal of Integrative Biology·Vural Özdemir
Jan 1, 2020·Computational and Structural Biotechnology Journal·Yitian Zhou, Volker M Lauschke
Jul 23, 2021·Science Translational Medicine·Maaike van der LeeSeyed Yahya Anvar
Nov 7, 2021·The Pharmacogenomics Journal·Maaike van der LeeSeyed Yahya Anvar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.